No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
No Data
12 Health Care Stocks Moving In Friday's Pre-Market Session
Bioxcel Therapeutics Restructures Credit and Strengthens Leadership
BioXcel Announces Common Stock and Warrants Offering, No Amount Given
BioXcel Therapeutics Announces Proposed Public Offering
Express News | BioXcel Therapeutics- as of Nov 18, ‘431 Patent Has Been Accepted for Listing in FDA Approved Drug Products With Therapeutic Equivalence Evaluations
Mizuho Securities Maintains BioXcel Therapeutics(BTAI.US) With Hold Rating, Announces Target Price $1